Rhythm Pharmaceuticals Stock
Rhythm Pharmaceuticals Stock
Rhythm Pharmaceuticals shows a slight decrease today, losing -€0.500 (-0.700%) compared to yesterday.
The stock is an absolute favorite of our community with 41 Buy predictions and no Sell predictions.
With a target price of 109 € there is a hugely positive potential of 53.52% for Rhythm Pharmaceuticals compared to the current price of 71.0 €.
Our community identified positive and negative aspects for Rhythm Pharmaceuticals stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Rhythm Pharmaceuticals stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Rhythm Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rhythm Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | -0.700% | -4.667% | -5.921% | 45.918% | -23.529% | 338.650% | 306.250% |
| Heron Therapeutics Inc. | -0.770% | 1.801% | -17.320% | -57.946% | -36.580% | -71.740% | -95.128% |
| Evolus Inc | -1.110% | 4.046% | -22.078% | -56.098% | -33.945% | -51.351% | -67.857% |
| Sangamo Therapeutics Inc. | 8.260% | -15.717% | -37.386% | -65.319% | -36.993% | -83.471% | -97.618% |
Comments
Rhythm Pharmaceuticals (RYTM) had its price target lowered by HC Wainwright from $110.00 to $100.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Citigroup Inc. from $136.00 to $131.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Royal Bank Of Canada from $140.00 to $130.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat